Testing the LIFE device to treat aortic aneurysm
Tests the LIFE device for treating swelling in the aorta in adults.
Key facts
- Who runs it
- Jonathan Bath
- Where
- Columbia, United StatesSee the site
- Trial code
- Registry title
- Laser In Situ Fenestration Study
- Status
- Recruiting
- People taking part
- 15 people, planned
- Started
- 15 Oct 2024
- Expected to end
- Jun 2033
- Type of study
- Interventional
- Treatments tested
- Fenestrated Endovascular Aneurysm Repair using the LIFE Device System
- Record updated
- 17 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a large aortic aneurysm (a swelling of the body's main blood vessel) near the kidney arteries. It tests a new laser device, the LIFE device, for repair from inside the vessel.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Aortic aneurysm in the juxtarenal or pararenal aorta, over 5.5 cm (2.2 in) in men or over 5.0 cm (2 in) in women, or growing fast with a high risk of bursting. The repair must cover the kidney and gut artery branches. The vessel shape and sizes must fit the device.
- Earlier treatment
- People cannot have open surgery, or open surgery carries high risk for them. Currently approved endovascular options are not possible for them. They are not willing or able to travel to sites with manufacturer-made trial devices.
Main reasons for not taking part
- Allergy to device materials, such as Nitinol, polyester, Platinum-Iridium, stainless steel, fluoropolymer or heparin
- Allergy or problem with blood thinners or contrast dye that cannot be managed
- A bleeding or clotting disorder that cannot be corrected
- Body size that blocks X-ray imaging of the aorta or is too large for the equipment
- Taking part in another study of an experimental therapy
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Aortic aneurysm >5.5 cm in a man or > 5.0 cm in a woman or rapid expansion deemed at significant risk for rupture in the juxtarenal or pararenal aorta
- Endovascular aortic repair requiring coverage of renovisceral branches
- Not candidate or at high risk for open repair. For example, but not exclusively, due to renal dysfunction, previous abdominal surgery, obese body habitus, previous coronary bypass grafts or high cardiac risk, chronic obstructive pulmonary disease (COPD) or on oxygen at rest, poorly controlled diabetes, current smoking, or antiplatelet or anticoagulation use
- Proximal aortic landing zone in Zone 5 of the aorta or previous graft of at least 10 mm in length and diameter of between 20 and 40 mm
- Distance ≥ 5 mm between top of graft fabric and renovisceral branch orifice
- At least a 5 mm iliofemoral artery to accept the endovascular stent graft device and an axillary brachial artery of sufficient diameter to accept the laser catheter
- Renovisceral diameter between 4 and 13 mm at the origin
- At the time of case planning, the patient's anatomy appears amenable to complete exclusion of the aneurysm with laser fenestration techniques
- Not willing or able to travel to sites that have access to manufacturer-made investigational endovascular devices
- Not a candidate for currently approved endovascular options
- 18 years or older
- Patient or legally authorized representative agrees to participate in the study and provides written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization
- Patient is able and willing to meet all study requirements, including participating in follow up evaluations and attending required assessment visits
Who cannot take part
- Concurrent participation in another research protocol for investigation of an experimental therapy
- Known sensitivities or allergies to the materials of construction of the devices, including Nitinol, polyester, Platinum-Iridium, stainless steel, fluoropolymer, and heparin
- Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed
- Uncorrectable coagulopathy
- Body habitus that would inhibit radiographic visualization of the aorta or exceeds the safe capacity of equipment
- Subject has been judged to be unsuitable for participation in the study by the Investigator for any reason
Where in United States
- University of Missouri - ColumbiaColumbia, United StatesContact: Jonathan Bath, MDTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn about a new device, named the LIFE device, to treat people with aneurysms (swellings) in the aorta (large, main blood vessel that delivers blood from the heart to the body). The main questions this trial aims to answer are:
Read full original descriptionShow less
* If the LIFE device works to treat aortic aneurysms * What medical problems participants have when the LIFE device is used Participants will undergo treatment with the LIFE device and thereafter at 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years have their pulses checked, bloodwork to check kidney function (BUN and serum creatinine), and a CT scan of the aneurysm area.
The group in the trial
- Endovascular Aneurysm RepairTreatment being tested
Fenestrated Endovascular Aneurysm Repair using the LIFE Device System
Treatment: Fenestrated Endovascular Aneurysm Repair using the LIFE Device System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Laser In Situ Fenestration for Endovascular Aortic Repair (LIFE) Study
- Plain-language title
- Testing the LIFE device to treat aortic aneurysmGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 17 September 2026